Literature DB >> 20656542

Endothelins and their receptors as biological markers for oral cancer.

Renata R Hoffmann1, Liliane S Yurgel, Maria M Campos.   

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common malignancies recognized nowadays, and represents a public health problem. Its early detection is the better alternative to provide a good quality of life for the patients. During the last years, several studies have identified potential biomarkers of OSCC progression and prognosis. Endothelins and their receptors are involved in several pathophysiological conditions and in various cancer types. The present review article discusses whether the endothelin system would represent a biomarker for OSCC. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656542     DOI: 10.1016/j.oraloncology.2010.06.015

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  4 in total

1.  Significance of serum butyrylcholinesterase levels in oral cancer.

Authors:  K Prabhu; D Naik; S Ray; A Rao; A Kamath
Journal:  Australas Med J       Date:  2011-07-31

2.  Role of endothelin receptor signalling in squamous cell carcinoma.

Authors:  Shunsuke Ishimoto; Koichiro Wada; Noriaki Tanaka; Tadashi Yamanishi; Kohji Ishihama; Tomonao Aikawa; Masaya Okura; Atsushi Nakajima; Mikihiko Kogo; Yoshinori Kamisaki
Journal:  Int J Oncol       Date:  2011-11-10       Impact factor: 5.650

Review 3.  Early detection and personalized treatment in oral cancer: the impact of omics approaches.

Authors:  Ilda Patrícia Ribeiro; Leonor Barroso; Francisco Marques; Joana Barbosa Melo; Isabel Marques Carreira
Journal:  Mol Cytogenet       Date:  2016-11-23       Impact factor: 2.009

4.  Clinicopathological Significance of the ET Axis in Human Oral Squamous Cell Carcinoma.

Authors:  Hiroki Miyazawa; Koroku Kato; Yutaka Kobayashi; Mariko Hirai; Iyo Kimura; Hiroko Kitahara; Natsuyo Noguchi; Hiroyuki Nakamura; Shuichi Kawashiri
Journal:  Pathol Oncol Res       Date:  2018-10-31       Impact factor: 3.201

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.